Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone

Autor: Rob ter Heine, John M. H. de Klerk, Rogier Lange, Jocye M. Van Dodewaard-de Jong, Alfons J.M. van den Eertwegh, Haiko J. Bloemendal, Henk M.W. Verheul, Esther W. Bouman-Wammes
Rok vydání: 2019
Předmět:
Male
Oncology
medicine.medical_specialty
Combination therapy
Urology
medicine.medical_treatment
030232 urology & nephrology
Bone Neoplasms
Castration resistant
Pain palliation
Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2]
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Drug Therapy
Quality of life
Internal medicine
Humans
Medicine
In patient
Radioisotopes
Clinical Trials as Topic
Chemotherapy
business.industry
Cancer Pain
medicine.disease
Combined Modality Therapy
Survival Analysis
Prostatic Neoplasms
Castration-Resistant
lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]
Treatment Outcome
Bone targeting
030220 oncology & carcinogenesis
Quality of Life
Radiopharmaceuticals
business
Radium
Zdroj: Clinical Genitourinary Cancer, 17, e281-e292
Bouman-Wammes, E W, de Klerk, J M H, Bloemendal, H J, Van Dodewaard-de Jong, J M, Lange, R, ter Heine, R, Verheul, H M W & Van den Eertwegh, A J M 2019, ' Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone ', Clinical Genitourinary Cancer, vol. 17, no. 2, pp. e281-e292 . https://doi.org/10.1016/j.clgc.2018.11.014
Clinical Genitourinary Cancer, 17, 2, pp. e281-e292
ISSN: 1558-7673
DOI: 10.1016/j.clgc.2018.11.014
Popis: Item does not contain fulltext In patients with metastatic castration-resistant prostate cancer, bone is the most common site for metastases. Because of their osteoblastic character, these lesions are very suitable for treatment with bone-seeking radiopharmaceuticals (RPs). Nowadays, radium-223-chloride is the only RP with a proven benefit in overall survival, whereas the beta-emitting RPs are used for pain palliation. In the past, many trials that investigated RPs alone, or in combination with chemotherapy have been performed. Because of different designs, characteristics of included patients, and chemotherapeutical and RP regimens, interpretation of the promising data and positioning of RPs in the treatment of metastatic prostate cancer has become difficult. In this review, we provide an overview of the existing data per RP with a focus on the different RPs in combination with chemotherapy. Furthermore, we aim to clarify the benefits on pain response and quality of life. Finally, we focus on the optimal timing and use of biomarkers in the treatment of patients with castration-resistant prostate cancer with RPs.
Databáze: OpenAIRE
Externí odkaz: